Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights [Yahoo! Finance]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Yahoo! Finance
Initiated RLY-2608 + fulvestrant + ribociclib triplet combination in PI3Ka-mutated HR+/HER2- metastatic breast cancer Approximately $750 million in cash, cash equivalents and investments at end of Q4 2023, expected to fund operations into second half of 2026 CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported fourth quarter and full year 2023 financial results and corporate highlights. “We made important progress across our portfolio during 2023, advancing multiple clinical programs and continuing to invest significantly in our research engine – the Dynamo platform,” said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. “We are very pleased with the RLY-2608 data disclosed to-date and how its clinical profile continued to mature throughout
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at HC Wainwright from $19.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Relay Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate HighlightsGlobeNewswire
- Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024GlobeNewswire
RLAY
Earnings
- 11/6/24 - Beat
RLAY
Sec Filings
- 11/6/24 - Form 10-Q
- 11/6/24 - Form 8-K
- 10/30/24 - Form 4
- RLAY's page on the SEC website